About Kinesin-like protein KIF18B
Kinesin-like protein KIF18B (KIF18B) is a protein
from Homo sapiens identified by UniProt accession
Q86Y91, 852 residues long.
MolForge cross-references it against 0 known binders and
95 disease associations.
Target properties
| Protein name | Kinesin-like protein KIF18B |
| UniProt accession | Q86Y91 |
| Gene | KIF18B |
| Organism | Homo sapiens |
| Length | 852 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q86Y91-F1 | alphafold | PREDICTED | 62.24 | — |
Amino-acid sequence (852 residues)
MAVEDSTLQV VVRVRPPTPR ELDSQRRPVV QVVDERVLVF NPEEPDGGFP GLKWGGTHDG PKKKGKDLTF VFDRVFGEAA TQQDVFQHTT HSVLDSFLQG YNCSVFAYGA TGAGKTHTML GREGDPGIMY LTTVELYRRL EARQQEKHFE VLISYQEVYN EQIHDLLEPK GPLAIREDPD KGVVVQGLSF HQPASAEQLL EILTRGNRNR TQHPTDANAT SSRSHAIFQI FVKQQDRVPG LTQAVQVAKM SLIDLAGSER ASSTHAKGER LREGANINRS LLALINVLNA LADAKGRKTH VPYRDSKLTR LLKDSLGGNC RTVMIAAISP SSLTYEDTYN TLKYADRAKE IRLSLKSNVT SLDCHISQYA TICQQLQAEV AALRKKLQVY EGGGQPPPQD LPGSPKSGPP PEHQPCTPEL PAGPRALQEE SLGMEAQVER AMEGNSSDQE QSPEDEDEGP AEEVPTQMPE QNPTHALPES PRLTLQPKPV VGHFSARELD GDRSKQLALK VLCVAQRQYS LLQAANLLTP DMITEFETLQ QLVQEEKIEP GAEALRTSGL ARGAPLAQEL CSESIPVPSP LCPEPPGYTG PVTRTMARRL SGPLHTLGIP PGPNCTPAQG SRWPMEKKRR RPSALEADSP MAPKRGTKRQ RQSFLPCLRR GSLPDTQPSQ GPSTPKGERA SSPCHSPRVC PATVIKSRVP LGPSAMQNCS TPLALPTRDL NATFDLSEEP PSKPSFHECI GWDKIPQELS RLDQPFIPRA PVPLFTMKGP KPTSSLPGTS ACKKKRVASS SVSHGRSRIA RLPSSTLKRP AGPLVLPELP LSPLCPSNRR NGKDLIRVGR ALSAGNGVTK VS
Explore Kinesin-like protein KIF18B with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets